UTHR News and Press, United Therapeutics Corporation From 01/18/24

2024-01-18 11:54:11 ET More on S&P 500 Index: The Window For A Significant Stock Market Decline Is Closing Industrial Production December 2023: No Landing = No Fed Rate Cuts Dollar Rally Pauses, But Fuel From Interest Rate Adjustment May Not Be Complete N...

2024-01-14 10:06:13 ET Summary Y-mAbs Therapeutics' shares have rebounded massively since March 2023 due to the company's restructuring, extending its cash runway until 2027. The company's main commercial asset is Danyelza, a monoclonal antibody for the treatment of neuroblastoma,...

2024-01-12 07:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...

2024-01-02 10:00:00 ET Summary United Therapeutics Corporation calls itself a "Public Benefit" company. The reality, it is a cynical monopolist about to lose its monopoly. If patent trolling fails, their premium to the entrant could collapse. Disclaimer . ...

2024-01-02 06:35:54 ET MannKind ( NASDAQ: MNKD ) has sold a 1% royalty in net sales of Tyvaso DPI (treprostinil) inhalation powder to Sagard Healthcare in exchange for up to $200M as part of a royalty purchase deal . The biopharmaceutical firm is entitled to a 10% royal...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42 nd Annual J.P. Morg...

2023-12-28 20:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-21 08:00:00 ET Summary The U.S. Court declares United Therapeutics' PAH treatment patent unpatentable, favoring Liquidia in the market. Liquidia's modest revenue increase and high R&D and G&A expenses lead to a wider net loss. Liquidia has strong short-term liq...

2023-12-20 12:00:32 ET Summary Liquidia Corporation is worth at least $15 in a win. Roivant Sciences is worth at least $12 per share. Burford Capital Limited is worth at least $20 per share. Value & Event Driven Investing I recently spoke for a half an hour a...